## Thymic Epithelial Tumours Histopathology Reporting Guide

ICCR

Given name(s)	
Patient identifiers Date of request Accession/Laboratory num	er
DD – MM – YYYY	
Elements in <b>black text</b> are CORE. Elements in grey text are NON-CORE.       SCOPE OF THIS DATASET         indicates multi-select values       indicates single select values	Ì
CLINICAL INFORMATION (select all that apply)	
○ Not provided	ified
Myasthenia gravis Great vessels	
Pure red cell aplasia Brachiocephalic (innominate) vein	
Rheumatoid arthritis       Left       Right       Laterality not spec         Lupus       Superior years cave	ified
Addison's disease       Extrapericardial pulmonary artery/veins         Cushing's disease       Aorta (ascending, arch or descending)	
Hypogammaglobulinemia (Good's syndrome)	
Previous neoplasm, <i>specify</i>	
Myocardium	
Preoperative therapy, <i>specify</i>	
Separate extrathymic tumour nodules, <i>specify</i>	
Other, <i>specify</i>	
OPERATIVE PROCEDURE	
O Not specified	
O Partial thymectomy	
Total thymectomy	
Extended thymectomy     SPECIMEN INTEGRITY	
Other, specify     O Intact specimen	
Surface disrupted	
Fragmented specimen	
SPECIMEN(S) SUBMITTED (select all that apply)	
Partial thymus          Not specified         Thymic	
Complete thymus	
Thymus plus surrounding tissue (extended thymectomy) $\bigcirc >1$ tumour	
Mediastinal pleura	
Anterior mediastinal (pre-vascular) mass	
Left Right	
Wedge biopsy Wedge biopsy MAXIMUM DIMENSION OF PRIMARY TUMOUR	
Upper lobe	
Lower lobe	
Lobectomy Lower lobe mm	
Upper lobe	
Lower lobe     Deper lobe     Middle lobe     Middle lobe	
Pneumonectomy       Middle lobe       BLOCK IDENTIFICATION KEY         Lower lobe       (List overleaf or separately with an indication of the	
Pneumonectomy       nature and origin of all tissue blocks)	

Use of this dataset is only permitted subject to the details described at: Disclaimer - International Collaboration on Cancer Reporting (iccr-cancer.org) Version 3.0 Published May 2022 ISBN: 978-1-922324-32-0 Page 1 of 4

HISTO	OGICAL	TUMOUR	TYPE	1001
-------	--------	--------	------	------

(Value list from the World Health Organization, Classification of Thoracic Tumours (2021))<sup>a</sup>

## Thursome

путота		
Not identified		
Present		
Predominant subtype		
		%
Other subtypes		
		%
	-	%
		%

#### Thymic carcinoma

O Not identified	
Present	
Prodominant	

## Predominant subtype

			%
(	Other subtypes		
		➡	%
[			
		-	%
[			%
		-	/0

## Thymic neuroendocrine tumours

○ Not identified	
🔘 Present	
▼ Typical carcinoid/ Neuroendocrine tumour, grade 1 →	%
Atypical carcinoid/ Neuroendocrine tumour, grade 2 ➡	%
<b>-</b>	L

#### Thymic neuroendocrine carcinomas

Not identified		
Present		[
Large cell neuroendocrine carcinoma		%
carcinoma		
Small cell carcinoma	$\rightarrow$	%

#### Final histological diagnosis

(Use 2021 WHO Classification for combined tumours)

aı	Where relevant,	if more than o	ne subtype,	list in 10% i	increments.

## EXTENT OF DIRECT INVASION

#### Thymus

- No invasion beyond capsule or limit of the thymus
- $\bigcirc$  Invasion beyond the mediastinum

## Mediastinal pleura

- () Not applicable
- Cannot be assessed
- Not involved
- ◯ Involved

#### Pericardium

- Not applicable
- Cannot be assessed
- Not involved
- Involved

#### Lung (pulmonary parenchyma, visceral pleura, or both)

- Not applicable
- $\bigcirc$  Cannot be assessed
- Not involved
- Involved, specify lobe(s) of the lung

#### Brachiocephalic (innominate) vein

- Not applicable
- Cannot be assessed
- Not involved
- Involved

## Superior vena cava

- Not applicable
- Cannot be assessed
- Not involved
- Involved

## Phrenic nerve

- O Not applicable
- Cannot be assessed
- Not involved
- Involved

## Extrapericardial pulmonary artery or veins

- Not applicable
- Cannot be assessed
- Not involved
- Involved

#### Aorta (ascending, arch or descending)

- Not applicable
- Cannot be assessed
- O Not involved
- Involved

## Arch vessels

- () Not applicable
- Cannot be assessed
- $\bigcirc$  Not involved
- Involved

### Intrapericardial pulmonary artery

- Not applicable
- Cannot be assessed
- Not involved
- Involved

Other involved organ(s)/site(s) by direct spread, specify

Use of this dataset is only permitted subject to the details described at: Disclaimer - International Collaboration on Cancer Reporting (iccr-cancer.org) Version 3.0 Published May 2022

ISBN: 978-1-922324-32-0

SEPARATE EXTRATHYMIC TUMOUR NODULES/METASTASES	LYMPH NODE STATUS
Pleural and/or pericardial	$\bigcirc$ No nodes submitted or found
O Not identified	Not involved
Present	Involved (select all that apply)
Specify location(s) Specify number/location	Anterior (perithymic) nodes (N1) Number of lymph nodes
$\rightarrow$	examined
$\rightarrow$	Number of positive lymph
	nodes
$\rightarrow$	$\bigcirc$ Number cannot be determined
Pulmonary intraparenchymal	Deep intrathoracic or cervical nodes (N2)
<ul> <li>Not identified</li> <li>Present</li> </ul>	Number of lymph nodes examined
$\overline{\mathbf{C}}$	Number of positive lymph
Distant organ	nodes
Present, <i>specify site(s)</i>	O Number cannot be determined
	Unspecified location within N1 or N2
	Number of lymph nodes examined
	Number of positive lymph nodes
RESPONSE TO NEOADJUVANT THERAPY	Number cannot be determined
<ul> <li>Cannot be assessed</li> <li>Prior treatment not known</li> </ul>	
<ul> <li>No prior treatment</li> </ul>	Location(s) outside N1 or N2 (M1b disease)
No response	Number of lymph nodes examined
Response present Percentage viable tumour <sup>b</sup> %	Number of positive lymph nodes
<sup>b</sup> If more than one tumour is present record the percent viable tumour in each.	Number cannot be determined
MARGIN STATUS	COEXISTENT PATHOLOGY (select all that apply)
Cannot be assessed	Thymic hyperplasia
<ul> <li>Not involved</li> </ul>	Follicular
↓ Involved	True
Macroscopic, <i>specify margin(s), if possible</i>	Upphoepithelial sialadenitis-like
	Cystic changes
	<ul> <li>In adjacent thymus</li> </ul>
	Other, <i>specify</i>
Microscopic, specify margin(s), if possible	•

Use of this dataset is only permitted subject to the details described at: Disclaimer - International Collaboration on Cancer Reporting (iccr-cancer.org) Version 3.0 Published May 2022 Page 3 of 4 ISBN: 978-1-922324-32-0

## ANCILLARY STUDIES

## Immunohistochemical markers<sup>c</sup>

- Not performed
- Performed

Positive markers	
Negative markers	
Equivocal markers	

#### Interpretation and conclusions

# Molecular studies

Not performed

Performed, specify test(s) and result(s)

Representative blocks for ancillary studies, specify those blocks best representing tumour and/or normal tissue for further study

<sup>c</sup> Applicable to all biopsies, thymectomy and resection specimens of thymic carcinomas and thymic neuroendocrine tumours.

## HISTOLOGICALLY CONFIRMED DISTANT METASTASES

Not identified

Present, specify site(s)

## PATHOLOGICAL STAGING

## TNM Staging for thymic epithelial tumours (UICC TNM 8th edition)<sup>d</sup>

**TNM Descriptors** (only if applicable) (select all that apply)

- m multiple primary tumours
- r recurrent
- y post-therapy

#### Primary tumour (pT)

 $\bigcirc$  TX<sup>e</sup> Primary tumour cannot be assessed () то No evidence of primary tumour ○ T1 Tumour encapsulated or extending into the mediastinal fat, may involve the mediastinal pleura ① T1a No mediastinal pleural involvement T1b Direct invasion of the mediastinal pleura ○ T2 Tumour with direct involvement of the pericardium (partial or full thickness) () тз Tumour with direct invasion into any of the following: lung, brachiocephalic vein, superior vena cava, phrenic nerve, chest wall, or extrapericardial pulmonary artery or vein ○ T4 Tumour with direct invasion into any of the following: aorta (ascending, arch or descending), arch vessels, intrapericardial pulmonary artery, myocardium, trachea or oesophagus

#### Regional lymph nodes (pN)

No nodes submitted or found

- NX<sup>e</sup> Regional lymph nodes cannot be assessed
- () NO No regional lymph node metastasis
- () N1 Metastasis in anterior (perithymic) lymph nodes
- 🔿 N2 Metastasis in deep intrathoracic or cervical lymph nodes

<sup>d</sup> Reproduced with permission. Source: UICC TNM Classification of Malignant Tumours, 8th Edition, eds by James D. Brierley, Mary K. Gospodarowicz, Christian Wittekind. 2016, Publisher Wiley. (incorporating any errata published up until 6<sup>th</sup> October 2020).

<sup>e</sup> *TX* and *NX* should be used only if absolutely necessary.

#### Masaoka-Koga staging for thymomas and thymic carcinoma

- Not applicable
- () Cannot be determined
- Grossly and microscopically completely () I encapsulated tumour
  - IIa Microscopic transcapsular invasion
  - 🔿 IIb Macroscopic invasion into thymic or surrounding fatty tissue, or grossly adherent to but not breaking through mediastinal pleura or pericardium
- Macroscopic invasion into neighbouring organ  $\bigcirc$  III (i.e., pericardium, great vessel or lung)
  - () IVa Pleural or pericardial metastases
  - IVb Lymphogenous or haematogenous metastases